Roche to Acquire HOOKIPA Pharma for $300M

TL;DR

Roche is buying HOOKIPA for $300M cash, deal expected to close H1 2025.

AI Summary

HOOKIPA Pharma Inc. announced on November 18, 2024, that it has entered into a definitive agreement to be acquired by Roche for $300 million in cash. This acquisition is expected to close in the first half of 2025, subject to customary closing conditions.

Why It Matters

This acquisition by a major pharmaceutical company like Roche could significantly impact HOOKIPA's pipeline and the development of its investigational therapies.

Risk Assessment

Risk Level: medium — The acquisition is subject to customary closing conditions, meaning there's a possibility it may not be completed.

Key Numbers

• $300M — Acquisition Price (Cash amount Roche will pay for HOOKIPA Pharma)

Key Players & Entities

• HOOKIPA Pharma Inc. (company) — Company filing the report and being acquired
• Roche (company) — Acquiring company
• $300 million (dollar_amount) — Cash purchase price for HOOKIPA Pharma
• November 18, 2024 (date) — Date of the definitive agreement
• first half of 2025 (date) — Expected closing period for the acquisition

FAQ

Key Financial Figures

• $0.0001 — e on which registered Common Stock, $0.0001 par value per share HOOK The Nasdaq

Filing Documents

• tm2429040d1_8k.htm (8-K) — 30KB
• 0001104659-24-121019.txt ( ) — 203KB
• hook-20241118.xsd (EX-101.SCH) — 3KB
• hook-20241118_lab.xml (EX-101.LAB) — 33KB
• hook-20241118_pre.xml (EX-101.PRE) — 22KB
• tm2429040d1_8k_htm.xml (XML) — 4KB

01 Other Events

Item 8.01 Other Events On November 18, 2024, HOOKIPA Pharma Inc. (the "Company") approved a plan to continue to improve its cost structure and operating efficiency, which includes a reduction in the Company's workforce by approximately 80% of the Company's then-current employee base (the "Restructuring Plan"). The Company expects to begin the implementation of the Restructuring Plan in the fourth quarter of 2024 and expects the Restructuring Plan to be substantially completed by the end of the first half of 2025. In connection with the Restructuring Plan, in an effort to rebalance the Company's cost structure in alignment with the Company's strategic refocus and development of its oncology portfolio, the Company also announced that it will pause clinical development in its eseba-vec program for the treatment of Human Papillomavirus 16-positive ("HPV16+") head and neck cancers, including an early termination of the Company's ongoing Phase 1/2 clinical trial for the treatment of HPV16+ cancers. The Company's early termination of its ongoing Phase 1/2 clinical trial for the treatment of HPV16+ is not due to lack of efficacy or adverse safety profiles. While the Company will continue to seek partnering opportunities for the eseba-vec program, the Company will focus primarily on progressing the phase 1-ready HB-700 program for the treatment of KRAS mutant cancers. I n April 2024, the Company received Investigational New Drug clearance from the U.S. Food and Drug Administration for HB-700 for the treatment of KRAS mutated cancers, including, lung, colorectal and pancreatic cancers. Notwithstanding the Company's Restructuring Plan and the immediate pause of the eseba-vec program, the Company continues to enroll patients in its ongoing Phase 1b clinical trial related to its Human Immunodeficiency Virus program, HB-500, being developed in a partnership with Gilead Sciences Inc. ("Gilead"). In addition, the Company continues to support its Hepatitis B program, HB-400, wh

Forward Looking Statements

Forward Looking Statements This Current Report on Form 8-K and other related materials may contain a number of "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including statements regarding HOOKIPA's expectations related to the extent, timing and plan of the Restructuring Plan. Forward-looking statements can be identified by terms such as "will," "intent," "expects," "plans," "potential," "would" or similar expressions and the negative of those terms. HOOKIPA has based these forward-looking statements largely on its current expectations and projections about future events and financial trends that it believes may affect its business, financial condition and results of operations. Although HOOKIPA believes that such statements are based on reasonable assumptions, forward-looking statements are neither promises nor guarantees and they are necessarily some of which cannot be predicted or quantified and some of which are beyond HOOKIPA's control, you should not rely on these forward-looking trials and studies may not be favorable; that one or more of HOOKIPA's product candidate programs will not proceed as planned for technical, scientific or commercial reasons; availability and timing of results from preclinical studies and clinical trials; uncertainty about regulatory approval to conduct clinical trials or to market a products; uncertainties regarding intellection property protection; and those risk and uncertainties described under the heading "Risk Factors" in HOOKIPA's Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission, and in any other subsequent filings made by HOOKIPA with th

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2024 HOOKIPA Pharma Inc. By: /s/ Terry Coelho Name: Terry Coelho Title: Executive Vice President and Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR